KU Hematology & Medical Oncology Review 2019

 

KU Hematology & Medical Oncology Review 2019
R

KU ASCO 2019 Updates on Hepatobiliary Cancer: Pembrolizumab vs. Best Supportive Care, Nivolumab Alone vs. Combo, and Genetic Targets

By KU Hematology & Medical Oncology Review 2019 FEATURING Raed Al-Rajabi
By KU Hematology & Medical Oncology Review 2019 FEATURING Raed Al-Rajabi
0 views
August 21, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira
Gastrointestinal
14:39
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Updates on Pancreatic Cancer: Maintenance Olaparib and …

Feat. R. Al-Rajabi
16:20
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Updates on Hepatobiliary Cancer: Pembrolizumab vs. Best…

Feat. R. Al-Rajabi
19:12
KU Hematology & Medical Oncology Review 2019

Management of Toxicities in Neoadjuvant (Perioperative) Chemotherapy…

Feat. W. Sun
18:29
KU Hematology & Medical Oncology Review 2019

Anti-PD-1 Therapy and Dose Modification in Advanced Gastroesophageal…

Feat. W. Sun